The objective of this research is to assess the impact of cardioprotective drugs on the risk of cardiovascular disease in people with diabetes who experienced severe hypoglycaemic episodes. People experiencing hypoglycaemia are mainly at risk of arrhythmic disorders, and the effect of cardioprotective drugs on disarrhytmias is different (i.e., β-blockers vs ACE-inhibitors). Using HES- and ONS-linked data, we aim to assess whether the protective effects of β-blockers differ in subjects with and without previous hypoglycaemia. A nested case-control study design will be used for the analysis to estimate the risk of cardiovascular and all-cause death by exposure in people with and without a previous episode of severe hypoglycaemia (interaction analysis).
CV events and all-cause mortality
Kamlesh Khunti - Chief Investigator - University of Leicester
Brian Thorsted - Collaborator - Novo Nordisk
Francesco Zaccardi - Collaborator - University of Leicester
Lise Lotte Nystrup Husemoen - Collaborator - Novo Nordisk